Jazz Pharmaceuticals, Inc. has announced that the FDA's Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee will review JZP-6 (sodium oxybate) for the treatment of fibromyalgia at a joint meeting on August 20, 2010. The target date for the FDA to complete its review of the New Drug Application is October 11, 2010.
If approved, sodium oxybate would be the fourth drug to receive approval for the treatment of fibromyalgia. Sodium oxybate is the active...

